RxDoctor Payments Data

Fakhriran Ghahari, MD

Family Medicine · Burbank, CANPI 1639183569

Payments from drug & device makers

$3,488in general payments, 2019–2025

Across 208 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$973
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$428
  • Lilly USA, LLC$386
  • Amgen$312
  • Phathom Pharmaceuticals, Inc.$290
  • Nestle Healthcare Nutrition Inc.$234
  • plus $865 from 17 others

What the payments were for

  • Food & beverage$3,488100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,488 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$10,362
Medicare patients
39
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium33$90,898
Metformin Hcl78$42,608
OzempicSemaglutide41$36,341
Diclofenac Sodium60$31,501
JardianceEmpagliflozin44$29,022
EliquisApixaban22$18,701
JanuviaSitagliptin Phosphate23$18,428
TrulicityDulaglutide13$12,012
Breo ElliptaFluticasone/Vilanterol30$11,458
MeloxicamMeloxicam, Submicronized24$10,602
JanumetSitagliptin Phos/Metformin Hcl17$9,416
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,762
Icosapent Ethyl26$7,567
VascepaIcosapent Ethyl18$6,806
Repatha SureclickEvolocumab11$6,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$81$29,02244 claims
MerckJanuvia, Janumet$137$27,84440 claims
GSKBreo Ellipta, Trelegy Ellipta$181$19,22042 claims
Lilly USA, LLCTrulicity, Humulin N$386$12,56126 claims
AbbVieLinzess$973$5,31911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →